KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Cost of Revenue (2016 - 2025)

Pfizer (PFE) has disclosed Cost of Revenue for 17 consecutive years, with $5.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 10.78% to $5.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $16.1 billion, a 9.99% decrease, with the full-year FY2025 number at $16.1 billion, down 9.99% from a year prior.
  • Cost of Revenue was $5.3 billion for Q4 2025 at Pfizer, up from $4.2 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $10.0 billion in Q2 2022 to a low of $2.8 billion in Q1 2025.
  • A 5-year average of $5.8 billion and a median of $5.3 billion in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 394.87% in 2021, then plummeted 62.57% in 2023.
  • Pfizer's Cost of Revenue stood at $9.9 billion in 2021, then crashed by 38.95% to $6.1 billion in 2022, then grew by 24.72% to $7.6 billion in 2023, then decreased by 21.86% to $5.9 billion in 2024, then decreased by 10.78% to $5.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Cost of Revenue are $5.3 billion (Q4 2025), $4.2 billion (Q3 2025), and $3.8 billion (Q2 2025).